AR106085A1 - Formulaciones de olanzapina de liberación sostenida - Google Patents
Formulaciones de olanzapina de liberación sostenidaInfo
- Publication number
- AR106085A1 AR106085A1 ARP160102864A ARP160102864A AR106085A1 AR 106085 A1 AR106085 A1 AR 106085A1 AR P160102864 A ARP160102864 A AR P160102864A AR P160102864 A ARP160102864 A AR P160102864A AR 106085 A1 AR106085 A1 AR 106085A1
- Authority
- AR
- Argentina
- Prior art keywords
- poly
- olanzapine
- sustained release
- acid
- pharmaceutically acceptable
- Prior art date
Links
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 title abstract 3
- 229960005017 olanzapine Drugs 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000013268 sustained release Methods 0.000 title abstract 2
- 239000012730 sustained-release form Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 4
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 abstract 2
- 239000002202 Polyethylene glycol Substances 0.000 abstract 2
- 229920002988 biodegradable polymer Polymers 0.000 abstract 2
- 239000004621 biodegradable polymer Substances 0.000 abstract 2
- 229920001577 copolymer Polymers 0.000 abstract 2
- 239000002552 dosage form Substances 0.000 abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- VSKXVGWORBZZDY-UHFFFAOYSA-N 2-hydroxypropanoic acid;oxepan-2-one Chemical compound CC(O)C(O)=O.O=C1CCCCCO1 VSKXVGWORBZZDY-UHFFFAOYSA-N 0.000 abstract 1
- 102000009027 Albumins Human genes 0.000 abstract 1
- 108010088751 Albumins Proteins 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 229920001661 Chitosan Polymers 0.000 abstract 1
- 229920002732 Polyanhydride Polymers 0.000 abstract 1
- 229920001710 Polyorthoester Polymers 0.000 abstract 1
- 150000001241 acetals Chemical class 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 abstract 1
- 239000005018 casein Substances 0.000 abstract 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 abstract 1
- 235000021240 caseins Nutrition 0.000 abstract 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 abstract 1
- 229920001308 poly(aminoacid) Polymers 0.000 abstract 1
- 229920000747 poly(lactic acid) Polymers 0.000 abstract 1
- 229940065514 poly(lactide) Drugs 0.000 abstract 1
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 abstract 1
- 229920002627 poly(phosphazenes) Polymers 0.000 abstract 1
- 229920001610 polycaprolactone Polymers 0.000 abstract 1
- 239000004632 polycaprolactone Substances 0.000 abstract 1
- 239000000622 polydioxanone Substances 0.000 abstract 1
- 229920006149 polyester-amide block copolymer Polymers 0.000 abstract 1
- 229920002635 polyurethane Polymers 0.000 abstract 1
- 239000004814 polyurethane Substances 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 239000001993 wax Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Biological Depolymerization Polymers (AREA)
Abstract
Métodos para tratar la esquizofrenia o el trastorno bipolar administrando por vía subcutánea una forma de dosificación de liberación sostenida de olanzapina, o una sal farmacéuticamente aceptable de la misma. También se describen métodos para administrar por vía subcutánea olanzapina, o una sal farmacéuticamente aceptable de la misma. Reivindicación 9: El método de acuerdo con la reivindicación 1, en donde la forma de dosificación farmacéutica además comprende por lo menos un polímero biodegradable. Reivindicación 10: El método de acuerdo con la reivindicación 9, en donde dicho por lo menos un polímero biodegradable es una poli(lactida), poli(glicolido), poli(lactida con glicolido), poli-1-(ácidos carboxílicos alifáticos), copolioxalatos, policaprolactona, polidioxanona, poli(orto carbonatos), poli(acetales), poli(ácido láctido-caprolactona), poliortoésteres, poli(ácido glicólico-captolactona), poli(aminoácido), poliésteramida, polianhídridos, polifosfacinas, poli(alquilato de alquileno), poliuretano biodegradable, polivinilpirrolidona, ácido polialcanoico, polietilenglicol, copolímero de polietilenglicol y poliortoéster, albúmina, quitosano, caseína, ceras o mezclas o copolímeros de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562221290P | 2015-09-21 | 2015-09-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR106085A1 true AR106085A1 (es) | 2017-12-13 |
Family
ID=57047342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160102864A AR106085A1 (es) | 2015-09-21 | 2016-09-21 | Formulaciones de olanzapina de liberación sostenida |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US20170079985A1 (es) |
| EP (2) | EP4331570A1 (es) |
| JP (2) | JP2018527397A (es) |
| KR (1) | KR20180054627A (es) |
| CN (2) | CN116942677A (es) |
| AR (1) | AR106085A1 (es) |
| AU (2) | AU2016328958B2 (es) |
| CA (1) | CA2998504C (es) |
| CL (1) | CL2018000727A1 (es) |
| DK (1) | DK3352735T3 (es) |
| EA (1) | EA201890788A1 (es) |
| ES (1) | ES2960753T3 (es) |
| FI (1) | FI3352735T3 (es) |
| HU (1) | HUE063850T2 (es) |
| IL (3) | IL295161A (es) |
| MX (2) | MX2018003380A (es) |
| NZ (1) | NZ740665A (es) |
| PL (1) | PL3352735T3 (es) |
| PT (1) | PT3352735T (es) |
| TW (1) | TWI798161B (es) |
| WO (1) | WO2017053346A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020511483A (ja) * | 2017-03-20 | 2020-04-16 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ | 徐放性オランザピン製剤 |
| CA3087698A1 (en) | 2018-01-05 | 2019-07-11 | Impel Neuropharma, Inc. | Intranasal delivery of olanzapine by precision olfactory device |
| PH12022550775A1 (en) * | 2019-12-20 | 2023-08-23 | Alar Pharmaceuticals Inc | Long-acting injectable formulations of ketamine pamoate salts |
| CN112587505A (zh) * | 2020-10-16 | 2021-04-02 | 长春斯菲尔生物科技有限公司 | 一种奥氮平双羟萘酸盐缓释微粒制剂及其制备方法 |
| WO2025188992A1 (en) * | 2024-03-06 | 2025-09-12 | Neurelis, Inc. | Oral film for rapid active delivery |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7833543B2 (en) | 1995-06-07 | 2010-11-16 | Durect Corporation | High viscosity liquid controlled delivery system and medical or surgical device |
| HRP20000181B1 (en) * | 1997-09-30 | 2006-07-31 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine formulation |
| US6495164B1 (en) | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
| US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
| DK1635875T3 (da) | 2003-06-26 | 2009-01-12 | Psivida Inc | In-situ-geldannende lægemiddeladministrationssystem |
| EP2633853A1 (en) | 2004-01-12 | 2013-09-04 | The Trustees of The University of Pennsylvania | Long-term delivery formulations and methods of use thereof |
| EP1576952A1 (en) | 2004-03-18 | 2005-09-21 | OctoPlus Technologies B.V. | Hydrogel microspheres with improved release profile |
| NL1026261C2 (nl) | 2004-05-25 | 2005-11-28 | Nanomi B V | Sproei inrichting met een nozzleplaat voorzien van structuren ter bevordering van self-breakup, een nozzleplaat, alsmede werkwijzen ter vervaardiging en toepassing van een dergelijke nozzleplaat. |
| MXPA06014095A (es) | 2004-06-04 | 2007-08-07 | Camurus Ab | Formulaciones de deposito de lipidos. |
| EA200701065A1 (ru) * | 2004-11-16 | 2007-12-28 | Элан Фарма Интернэшнл Лтд. | Инъецируемые составы, содержащие нанодисперсный оланзапин |
| CA2603189A1 (en) * | 2005-04-13 | 2006-10-19 | Pfizer Products Inc. | Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles |
| RU2407529C2 (ru) * | 2005-04-13 | 2010-12-27 | Пфайзер Продактс Инк. | Инъецируемые препаративные формы депо и способы обеспечения замедленного высвобождения композиций, состоящих из наночастиц |
| ATE552032T1 (de) * | 2005-07-14 | 2012-04-15 | Lithera Inc | Verbesserte lipolytikum-formulierung mit hinhaltender wirkstofffreigabe für die arealbehandlung von fettgewebe |
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| US20070254832A1 (en) * | 2006-02-17 | 2007-11-01 | Pressler Milton L | Methods for the treatment of macular degeneration and related eye conditions |
| WO2007139744A2 (en) | 2006-05-23 | 2007-12-06 | Titan Pharmaceuticals, Inc. | Implantable polymeric device for sustained release of buprenorphine with minimal initial burst |
| MX2009000434A (es) | 2006-07-11 | 2009-01-29 | Qps Llc | Composiciones farmaceuticas para la distribucion de liberacion sostenida de peptidos. |
| FI20070174A0 (fi) | 2007-02-28 | 2007-02-28 | Delsitech Oy | Menetelmä silikakoostumusten valmistamiseksi, silikakoostumukset ja niiden käytöt |
| KR100805208B1 (ko) | 2007-03-27 | 2008-02-21 | 주식회사 펩트론 | 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법 |
| NZ580700A (en) | 2007-04-19 | 2012-01-12 | Dong A Pharm Co Ltd | A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof |
| EP2152315B1 (en) | 2007-05-25 | 2016-01-06 | Indivior UK Limited | Sustained delivery formulations of risperidone compounds |
| ES2324009B1 (es) | 2007-11-23 | 2010-05-21 | Gp Pharm S.A. | Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo. |
| JP5222550B2 (ja) * | 2007-12-27 | 2013-06-26 | 財團法人工業技術研究院 | 徐放性組成物およびその製造方法 |
| US20090181068A1 (en) | 2008-01-14 | 2009-07-16 | Dunn Richard L | Low Viscosity Liquid Polymeric Delivery System |
| US20090263443A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedics, Inc. | Methods for treating post-operative effects such as spasticity and shivering with clondine |
| CA2726763A1 (en) | 2008-06-03 | 2009-12-10 | Tolmar Therapeutics, Inc. | Controlled release copolymer formulation with improved release kinetics |
| WO2010018159A1 (en) | 2008-08-12 | 2010-02-18 | Novartis Ag | Pharmaceutical compositions |
| PT2355853T (pt) | 2008-10-10 | 2017-03-15 | Polyactiva Pty Ltd | Conjugados polímero biodegradável ¿ unidade bioativa |
| EA201100765A1 (ru) | 2008-12-15 | 2012-04-30 | Бинд Биосаиэнсис | Наночастицы длительной циркуляции для замедленного высвобождения терапевтических средств |
| WO2010105093A2 (en) | 2009-03-12 | 2010-09-16 | Delpor, Inc. | Implantable device for long-term delivery of drugs |
| WO2011042453A1 (en) | 2009-10-06 | 2011-04-14 | Ascendis Pharma As | Subcutaneous paliperidone composition |
| PT3536333T (pt) | 2010-01-04 | 2022-11-11 | Mapi Pharma Ltd | Sistema de depósito compreendendo acetato de glatirâmero |
| EP2343046A1 (en) | 2010-01-08 | 2011-07-13 | Nirvana's Tree House B.V. | Functionalised triblock copolymers and compositions containing such polymers |
| HRP20211853T1 (hr) | 2010-05-31 | 2022-03-04 | Laboratorios Farmaceuticos Rovi, S.A. | Sastavi in situ injekcijskih biorazgradivih implantata |
| UA111162C2 (uk) | 2010-08-04 | 2016-04-11 | Флекшен Терап'Ютікс, Інк. | Ін'єкційна композиція ацетоніду триамцинолону для лікування болю |
| FR2968994B1 (fr) | 2010-12-17 | 2012-12-28 | Flamel Tech Sa | Procede de preparation de nanoparticules |
| AU2011350898B2 (en) | 2010-12-29 | 2016-09-08 | Medincell | Biodegradable drug delivery compositions |
| PL2717914T3 (pl) | 2011-06-10 | 2020-05-18 | Ramscor, Inc. | Formulacje o przedłużonym uwalnianiu do dostarczania białek do oka i sposoby ich wytwarzania |
| HUE035214T2 (hu) | 2011-10-24 | 2018-05-02 | Braeburn Pharmaceuticals Inc | Beültethetõ hatóanyag adagoló készítmények és az ezekkel végzett kezelési eljárás |
| KR20200133286A (ko) | 2012-01-23 | 2020-11-26 | 알러간, 인코포레이티드 | 고화 디포-형성 주사가능 약물 제형에 현탁된 서방형 생분해성 또는 생체흡수성 미소구체 또는 미립자 |
| CN103417492A (zh) * | 2012-05-25 | 2013-12-04 | 上海现代药物制剂工程研究中心有限公司 | 含有奥氮平的生物降解微球制剂及其制备方法 |
| US20140323517A1 (en) | 2013-04-30 | 2014-10-30 | Heron Therapeutics, Inc. | Compositions and methods for injection of a biodegradable polymer-based delivery system |
| AU2014283692B2 (en) | 2013-06-20 | 2017-04-27 | Pharmathen S.A. | Preparation of polylactide-polyglycolide microparticles having a sigmoidal release profile |
| CN103877005A (zh) * | 2014-03-26 | 2014-06-25 | 陈德香 | 一种复方奥氮平皮下埋植缓释剂 |
-
2016
- 2016-09-21 ES ES16775424T patent/ES2960753T3/es active Active
- 2016-09-21 KR KR1020187007791A patent/KR20180054627A/ko not_active Ceased
- 2016-09-21 CN CN202310947482.0A patent/CN116942677A/zh active Pending
- 2016-09-21 AU AU2016328958A patent/AU2016328958B2/en active Active
- 2016-09-21 PL PL16775424.1T patent/PL3352735T3/pl unknown
- 2016-09-21 PT PT167754241T patent/PT3352735T/pt unknown
- 2016-09-21 MX MX2018003380A patent/MX2018003380A/es unknown
- 2016-09-21 EP EP23193256.7A patent/EP4331570A1/en active Pending
- 2016-09-21 DK DK16775424.1T patent/DK3352735T3/da active
- 2016-09-21 EA EA201890788A patent/EA201890788A1/ru unknown
- 2016-09-21 TW TW105130439A patent/TWI798161B/zh active
- 2016-09-21 CA CA2998504A patent/CA2998504C/en active Active
- 2016-09-21 WO PCT/US2016/052757 patent/WO2017053346A1/en not_active Ceased
- 2016-09-21 IL IL295161A patent/IL295161A/en unknown
- 2016-09-21 JP JP2018515050A patent/JP2018527397A/ja active Pending
- 2016-09-21 HU HUE16775424A patent/HUE063850T2/hu unknown
- 2016-09-21 EP EP16775424.1A patent/EP3352735B1/en active Active
- 2016-09-21 FI FIEP16775424.1T patent/FI3352735T3/fi active
- 2016-09-21 NZ NZ740665A patent/NZ740665A/en unknown
- 2016-09-21 CN CN201680066464.XA patent/CN108289834A/zh active Pending
- 2016-09-21 AR ARP160102864A patent/AR106085A1/es not_active Application Discontinuation
- 2016-09-21 US US15/271,508 patent/US20170079985A1/en not_active Abandoned
-
2018
- 2018-03-13 IL IL258086A patent/IL258086A/en unknown
- 2018-03-16 MX MX2022007315A patent/MX2022007315A/es unknown
- 2018-03-20 CL CL2018000727A patent/CL2018000727A1/es unknown
- 2018-05-17 US US15/982,449 patent/US20180264001A1/en not_active Abandoned
-
2020
- 2020-06-29 IL IL275735A patent/IL275735A/en unknown
-
2021
- 2021-07-01 JP JP2021110240A patent/JP2021167331A/ja active Pending
-
2022
- 2022-06-23 US US17/847,685 patent/US20220323458A1/en not_active Abandoned
- 2022-07-18 AU AU2022206695A patent/AU2022206695A1/en not_active Abandoned
-
2024
- 2024-04-01 US US18/623,327 patent/US20240238307A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR106085A1 (es) | Formulaciones de olanzapina de liberación sostenida | |
| CY1124369T1 (el) | Συνθεση εμφυτευματος ρισπεριδονης ή/και παλιπεριδονης | |
| WO2018183224A3 (en) | Injectable and biodegradable polymer formulations for controlled release of bioligic agents | |
| CY1122771T1 (el) | Φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης για τη χορηγηση πρωτεϊνων στον οφθαλμο και μεθοδοι για την παρασκευη αυτων | |
| AR097973A1 (es) | FORMULACIÓN FARMACÉUTICA QUE COMPRENDE HORMONA LIBERADORA DE GONADOTROPINA (GnRH), UN AGONISTA DE GnRH O UN ANTAGONISTA DE GnRH Y MÉTODO DE TRATAMIENTO | |
| AR088250A1 (es) | Forma de dosificacion farmaceutica oral resistente a alteracion comprendiendo agonista opioide y antagonista opioide | |
| CO7160109A2 (es) | Formulación de implantes de paliperidona | |
| UA111162C2 (uk) | Ін'єкційна композиція ацетоніду триамцинолону для лікування болю | |
| PE20142332A1 (es) | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas | |
| JP2018521120A5 (es) | ||
| CY1125446T1 (el) | Λιποσωμικο σκευασμα για χρηση στη θεραπεία καρκινου | |
| UY38673A (es) | Producto farmacéutico combinado que contiene leuprolido, un polímero biodegradable y gnrh o agonista | |
| EA201691884A1 (ru) | Получение загруженных пептидом микросфер на основе plga с характеристиками контролированного высвобождения | |
| CR20210480A (es) | Formulaciones farmacéuticas | |
| RU2016137289A (ru) | Схема применения соединения fgf-18 | |
| AR119614A1 (es) | Formas en estado sólido de (s)-2-(((s)-6,8-diflúor-1,2,3,4-tetrahidronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida y usos de la misma | |
| AR112166A1 (es) | Composiciones terapéuticas y métodos para el tratamiento de hepatitis b | |
| JP2018527397A5 (es) | ||
| JP2012102105A5 (es) | ||
| MX388028B (es) | Suministro de antioxidantes bioactivos, nanoencapsulados. | |
| AR062979A1 (es) | Formulaciones orales liofilizadas de desintegracion rapida de un antagonista del receptor de trombina | |
| MX2021009344A (es) | Composiciones con aminoacidos para el uso y tratamiento de lesiones del sistema nervioso central. | |
| AR034044A1 (es) | Composicion para el tratamiento reconstituyente en enfermedades de cartilago | |
| ZA202403104B (en) | Pharmaceutical formulation comprising tacrolimus, method for the preparation thereof and use | |
| EA202192534A1 (ru) | Системы стабилизации и контролируемого высвобождения для лекарственных средств, нестабильных при стерилизации |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |